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1014Baseline Predictors of 12-Month Treatment
Response to Ranibizumab in Patients With Wet
Age-Related Macular DegenerationCARL D. REGILLO, BRANDON G. BUSBEE, ALLEN C. HO, BEIYING DING, AND ZDENKA HASKOVA PURPOSE: To identify baseline characteristics predic-
tive of visual acuity (VA) outcomes at month 12 (M12)
and treatment frequency in the first 12 months of the
phase III HARBOR study.
 DESIGN: Retrospective, exploratory analysis of multi-
center randomized controlled trial data.
 METHODS: SETTING: Randomized, multicenter. STUDY
POPULATION: Patients aged ‡50 years with subfoveal wet
age-related macular degeneration (AMD) who had best-
corrected VA (BCVA) values measured at baseline and
M12. INTERVENTION: Intravitreal ranibizumab 0.5 mg
administeredmonthly (n[ 249) or as needed (PRN) after
3 monthly loading doses (n [ 251). MAIN OUTCOME
MEASURES: BCVA change from baseline at M12, percent-
age of patients who gained ‡15 letters (3 lines) in BCVA
from baseline at M12, and percentage of patients who
achieved ‡20/40 vision (Snellen) at M12 served as the ba-
sis for analyzing baseline predictors of observed VA out-
comes in the monthly and PRN groups. Total number of
ranibizumab PRN injections in the first 12 months was
also evaluated. Only variables that were statistically signif-
icant (P< .05) remained in the final statistical models.
 RESULTS: Baseline predictors of BCVA change from
baseline atM12 and/or percentage of 3-line gainers included
lowerBCVA,younger age, smaller total choroidalneovascu-
larization (CNV) leakage area, smaller area of occult CNV,
andpresenceof subretinalfluid (SRF).Baselinepredictors of
‡20/40 vision at M12 included higher BCVA, smaller total
CNV leakage area, and presence of SRF. SRF thickness
>118.25mmatbaseline predicted requiringmore ranibizu-
mab injections in the first 12 months of treatment.
 CONCLUSIONS: Select baseline characteristics have
predictive value for visual prognosis and treatment
frequency in ranibizumab-treated patients with wet
AMD. (Am J Ophthalmol 2015;160(5):1014–1023.
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LTHOUGH MOST PATIENTS WITH NEOVASCULAR
age-related macular degeneration (wet AMD)
experience improvements in visual and anatomic
outcomes with anti–vascular endothelial growth factor
(anti-VEGF) therapy, a subset of patients do not respond
optimally to treatment. For example, despite significant vi-
sual improvements in the majority of patients treated with
ranibizumab (Lucentis; Genentech, Inc, South San Fran-
cisco, California, USA) in the ANCHOR (Anti-VEGF
Antibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in Age-Related Macular
Degeneration)1,2 and MARINA (Minimally Classic/
Occult Trial of the Anti-VEGF Antibody Ranibizumab
in the Treatment of Neovascular AMD)3 trials,w10% of
patients in ANCHOR and w8%–10% of patients in
MARINA lost >_15 letters in best-corrected visual acuity
(BCVA) from baseline at month 24.1–3 Findings from
several retrospective studies suggest that certain
demographic and choroidal neovascularization (CNV)
lesion characteristics at baseline may increase the
likelihood of having better or worse treatment
outcomes.4–6 The elucidation of demographic, anatomic/
imaging, and functional characteristics at baseline that
can be used as predictive biomarkers of response to anti-
VEGF treatments will be helpful for the successful develop-
ment of next-generation treatments for wet AMD.
Historically, smaller CNV lesion sizes at baseline are
generally associated with better visual acuity (VA) out-
comes at month 24 in patients with subfoveal wet AMD,
as shown in the TAP (Treatment of Age-Related Macular
Degeneration With Photodynamic Therapy) and VIP
(Verteporfin in Photodynamic Therapy) trials.7 Retrospec-
tive analyses of 12-month data from ANCHOR4 and
24-month data from MARINA5 demonstrated that lower
baseline BCVA, smaller baseline CNV lesion size, and
younger baseline age were predictive of better VA out-
comes in ranibizumab-treated patients with wet AMD.4,5
These baseline predictors of visual outcomes were also
observed in a retrospective analysis of ranibizumab- or
bevacizumab-treated patients with wet AMD who
completed the first year of CATT (Comparison of Age-
Related Macular Degeneration Treatments Trials).6
The HARBOR (Phase III, Double-Masked, Multicenter,
Randomized, Active treatment-controlled Study of the Ef-
ficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab
Administered Monthly or on an As-needed Basis [PRN]0002-9394
http://dx.doi.org/10.1016/j.ajo.2015.07.034
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in Patients With Subfoveal Neovascular Age-Related
Macular Degeneration) trial provides a large prospective
data set on ranibizumab-treated patients with wet AMD.8
At the end of the first year of HARBOR (the primary
endpoint), clinically meaningful and similar improvements
in BCVA were observed across all treatment groups.8
The mean change from baseline in BCVA at month 12,
based on the last-observation-carried-forward method,
was þ10.1 letters (0.5 mg monthly; n ¼ 275), þ8.2 letters
(0.5 mg PRN; n ¼ 275), þ9.2 letters (2.0 mg monthly;
n ¼ 274), and þ8.6 letters (2.0 mg PRN; n¼ 273).8 These
improvements were achieved with a mean of 7.7 and 6.9
injections in the 0.5 mg and 2.0 mg PRN groups, respec-
tively, and a mean of 11.3 and 11.2 injections in the
0.5 mg and 2.0 mgmonthly groups, respectively.8 Although
the prespecified superiority and noninferiority comparisons
were not met at year 1, the HARBOR study 1-year results
demonstrated that ranibizumab 0.5 mg administered on a
monthly or PRN regimen, guided by VA and strict
spectral-domain optical coherence tomography (SD-OCT)
re-treatment criteria, resulted in clinically meaningful VA
gains in patients with wet AMD.8
This retrospective, exploratory analysis of data from the
HARBOR study investigated demographic and baseline
characteristics predictive of VA outcomes at month 12 in
the ranibizumab 0.5 mg monthly and 0.5 mg PRN groups,
and treatment frequency in the first 12 months in the rani-
bizumab 0.5 mg PRN group. The ranibizumab 0.5 mg dose
was chosen because it is the approved dosage for the treat-
ment of wet AMD,9 and is thus the most useful to clinicians
in the context of evaluating baseline predictors of treat-
ment response. Understanding which demographic and
ocular characteristics at baseline can be used as predictive
biomarkers of response to anti-VEGF treatment may help
retina specialists design optimal treatment plans tailored
from the start of therapy to individual patients with wet
AMD.METHODS
 STUDY DESIGN AND PATIENT ELIGIBILITY: The
methods for the HARBOR study have been reported previ-
ously.8 Briefly, HARBOR was a 24-month, phase III, ran-
domized, multicenter, double-masked, active-treatment
controlled study that evaluated the efficacy and safety of
intravitreal ranibizumab 0.5 mg and 2.0 mg administered
monthly or PRN after 3 monthly loading doses in treat-
ment-naı¨ve patients (n¼ 1097) aged >_50 years with active
subfoveal wet AMD (predominantly classic, minimally
classic, or purely occult CNV) and baseline BCVA of 20/
40–20/230 (Snellen equivalent).8 Re-treatment in the
PRN groups was based on BCVA using Early Treatment
Diabetic Retinopathy (ETDRS) charts and SD OCT
criteria. The study was conducted in accordance withVOL. 160, NO. 5 BASELINE PREDICTORS OF RESPONSEGood Clinical Practice guidelines (International Confer-
ence on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use E6), appli-
cable US Food and Drug Administration regulations, and
the Health Insurance Portability and Accountability Act.
The study protocol was approved by institutional review
boards at each location prior to study initiation, and all
participants provided written informed consent. The
HARBOR study is registered at ClinicalTrials.gov (no.
NCT00891735).
 OUTCOME MEASURES: The primary endpoint of the
HARBOR study was the mean change from baseline in
BCVA at month 12.8 In this retrospective, exploratory
analysis of multicenter, randomized, controlled data from
the HARBOR trial, the main outcome measures that
served as a basis for baseline predictors of VA outcomes
at month 12 were BCVA change from baseline at month
12, the proportion of patients with a BCVA gain of >_15
ETDRS letters from baseline at month 12, and the propor-
tion of patients with a Snellen equivalent of 20/40 or better
at month 12 in the ranibizumab 0.5 mgmonthly and 0.5 mg
PRN groups. A post hoc analysis of the total number of
injections in the first 12 months in patients receiving rani-
bizumab 0.5 mg PRN was also performed.
 STATISTICAL METHODS: These exploratory analyses
were performed on observed data from patients in the rani-
bizumab 0.5 mg monthly (n ¼ 249) and 0.5 mg PRN (n ¼
251) treatment groups who had BCVA values measured at
both baseline and month 12. A multivariate linear regres-
sion model was performed to determine baseline predictors
for BCVA change from baseline at month 12. Multivariate
analysis using logistic regression models was performed to
determine baseline predictors for BCVA gain of >_15 letters
from baseline at month 12 and baseline predictors for
Snellen equivalent of 20/40 or better at month 12. Propor-
tional odds and linear regression models were used to deter-
mine baseline predictors for the total number of injections
in the 0.5 mg PRN group during the first 12 months of the
study. Final models included only significant (P< .05) pre-
dictors selected by stepwise selection methods. All analyses
were exploratory in nature and no multiplicity adjustment
was made. All analyses were conducted using SAS software
version 9.2 (SAS Institute, Inc, Cary, North Carolina,
USA).
To better facilitate interpretation of the data and illus-
trate the trends graphically, a Classification and Regression
Tree (CART) analysis10 was used to dichotomize values for
continuous baseline predictors from the final models where
appropriate. All cutoff values were derived using CART
v6.0 (Salford Systems, San Diego, California, USA). A to-
tal of 44 variables (demographic parameters, baseline char-
acteristics, and assessments) were included in the statistical
modeling; for predictors of visual outcome, regimen
(monthly vs PRN) was also included in the candidate list.1015TO RANIBIZUMAB IN WET AMD
TABLE. Patient Demographics, Baseline Characteristics, and Assessments Included in the Statistical Modeling of Baseline Predictors
of 12-Month Treatment Response to Ranibizumab in Patients with Wet Age-Related Macular Degeneration
Variables that were baseline predictors of visual outcomes at month 12
Age; BCVA; area of occult CNV with no classic component; total CNV leakage area; subretinal fluid presencea
Variables that were baseline predictors of treatment frequency in the first 12 months
Subretinal fluid thicknessa
Variables that were NOT baseline predictors of visual outcomes or treatment frequency
Sex
Race
Ethnicity
Current smoking status
Lens status
Treatment regimen (monthly vs PRN)
Central foveal thickness
Central subfield thickness
Area of classic CNV
Percentage of classic CNV area
CNV classification
Evidence of fluid from CNV
Percentage of total CNV area
Area of subretinal fibrous tissue
Percentage of subretinal fibrous tissue
Greatest linear dimension of lesion
Percentage of occult CNV with no classic
component
Area of other lesion component with no CNV
PED
PED thickness
Presence of blood
Presence of classic CNV
Presence of fibrous tissue
Presence of neovascular AMD
Presence of occult CNV
Presence of photocoagulation scar
Presence of serous PED
Total macular volume
Total area of CNV
Total area of lesion
Macula dryb
Macula dry-2b
Macula totally dryb
Macula totally dry-2b
Retina dryb
Retina dry-2b
Retinal fluid atrophy (none, extrafoveal,
remote, subfoveal)
RPE rip (none, outside,b remote,b subfoveal)
AMD ¼ age-related macular degeneration; BCVA ¼ best-corrected visual acuity; CNV ¼ choroidal neovascularization; PED ¼ pigment
epithelial defect; RPE ¼ retinal pigment epithelium.
aBaseline predictors are variables that were statistically significant (P < .05) in the final model.
bSee Appendix (Supplemental Material available at AJO.com) for definition, as provided by the Digital Angiography Reading Center (DARC).RESULTS
PATIENT DEMOGRAPHICS AND BASELINE OCULAR CHARAC-
teristics for the study eye, previously reported, were well
balanced among the ranibizumab treatment arms.8 In the
0.5 mg monthly and 0.5 mg PRN groups, mean VA at base-
line was 54.2 and 54.5 letters (approximate Snellen equiv-
alent of 20/80), respectively, and the mean age at baseline
was approximately 79 years. Overall, approximately 46% of
patients in the 0.5 mg monthly and 0.5 mg PRN groups had
minimally classic CNV lesions, 16% had predominantly
classic lesions, and 37% had purely occult CNV. Total
area of CNV leakage and total area of CNV in the 2 treat-
ment groups ranged from 3.31 to 3.48 disc area (DA) and
from 3.04 to 3.27 DA, respectively.8 The mean baseline
area of occult CNV in the 0.5 mg monthly and 0.5 mg
PRN arms were 2.81 DA and 2.59 DA, respectively.
Approximately 76% of all patients had subretinal fluid
(SRF) present at baseline, and the average baseline SRF
thickness (including patients with no SRF) was 120.0 mm
and 129.7 mm (median, 109.5 mm and 111.0 mm) in the
0.5 mg monthly and 0.5 mg PRN groups, respectively. In
these retrospective, exploratory analyses of the HARBOR
study, 6 of 44 variables were found to be significant baseline
predictors of visual outcomes and/or injection frequency
(Table).1016 AMERICAN JOURNAL OF BASELINE PREDICTORS FOR BEST-CORRECTED VISUAL
ACUITY CHANGE AT MONTH 12: Significant baseline
predictors for BCVA change at month 12 in patients
who had both baseline and month 12 BCVA values
included baseline BCVA, age, and total CNV leakage
area and area of occult CNV.
Lower (ie, worse) BCVA at baseline predicted greater
mean gains in BCVA at month 12 (Figure 1). Patients
with baseline BCVA <_44 letters (approximate Snellen
equivalent of 20/125; n ¼ 103; gray circles) gained an
average of 15.3 letters at month 12 compared with a
mean gain of 8.2 letters in patients with baseline BCVA
>44 letters (approximate Snellen equivalent of 20/125 or
better; n ¼ 397; black circles). Younger age at baseline
also predicted greater mean gain in BCVA at month 12
(Figure 2). Patients aged <_73 years at baseline (n ¼ 116;
gray circles) gained a mean of 13.1 letters at month 12
compared with a mean gain of 8.6 letters in patients aged
>73 years at baseline (n ¼ 384; black circles).
Smaller total CNV leakage area at baseline and area of
occult CNV were also predictive of greater mean gains in
BCVA at month 12 (Figure 3). Patients with baseline total
CNV leakage area <_5.24 DA and baseline area of occult
CNV <_5.47 DA at baseline (n ¼ 415; Left panel) had a
greater mean gain in BCVA at month 12 (þ10.7 letters)
than did patients with total CNV leakage area >5.24 DANOVEMBER 2015OPHTHALMOLOGY
FIGURE1. Lower (ie, worse) best-corrected visual acuity at baseline predicted, on average, greater mean gain in best-corrected visual
acuity at month 12 in patients treated with ranibizumab for wet age-related macular degeneration. Data shown are for patients in the
ranibizumab 0.5 mg monthly and 0.5 mg as-needed groups who had best-corrected visual acuity measured at both baseline and month
12. Dashed line[ fitted simple linear regression line. BCVA[ best-corrected visual acuity.
FIGURE 2. Younger age at baseline predicted, on average, greater mean gain in best-corrected visual acuity at month 12 in patients
treated with ranibizumab for wet age-related macular degeneration. Data shown are for patients in the ranibizumab 0.5 mg monthly
and 0.5 mg as-needed groups who had best-corrected visual acuity measured at both baseline and month 12. Dashed line [ fitted
simple linear regression line. BCVA[ best-corrected visual acuity.and area of occult CNV >5.47 DA (n ¼ 51; þ8.9 letters;
Middle panel). Patients with smaller total CNV leakage
area <_5.24 DA and area of occult CNV <_5.47 DA at base-
line also had greater mean gains than did patients with to-
tal CNV leakage area >5.24 DA and area of occult CNV
<_5.47 DA (n ¼ 34; 3.0 letters; Right panel).
 BASELINE PREDICTORS FOR BEST-CORRECTED VISUAL
ACUITY GAIN ‡15 LETTERS AT MONTH 12: Significant
baseline predictors for BCVA gain >_15 letters at month
12 in patients who had both baseline and month 12
BCVA values included BCVA and total CNV leakage
area with SRF present.VOL. 160, NO. 5 BASELINE PREDICTORS OF RESPONSELower (ie, worse) BCVA at baseline predicted a greater
likelihood of gaining >_15 letters at month 12 (Figure 4).
Among patients with baseline BCVA <_68 letters (approx-
imate Snellen equivalent of 20/40 or worse; n¼ 438), 37%
gained >_15 letters at month 12 vs 11% of patients with
baseline BCVA >68 letters (approximate Snellen equiva-
lent better than 20/40; n ¼ 62; odds ratio [OR], 4.6; 95%
confidence interval [CI] 2.1–10.5; from logistic regression
model with baseline BCVA, baseline total CNV leakage
area, and SRF presence at baseline as covariates).
Smaller total CNV leakage area with SRF present at
baseline also predicted a greater likelihood of BCVA gain
>_15 letters at month 12 (Figure 5). In patients with SRF1017TO RANIBIZUMAB IN WET AMD
FIGURE 3. Smaller total choroidal neovascularization leakage area at baseline and area of occult choroidal neovascularization
predicted, on average, greater mean gain in best-corrected visual acuity at month 12 in patients treated with ranibizumab for wet
age-related macular degeneration. Data shown are for patients in the ranibizumab 0.5 mg monthly and 0.5 mg as-needed groups
who had best-corrected visual acuity measured at both baseline and month 12. Vertical bars are ±1 standard error of the mean.
BCVA[ best-corrected visual acuity; CNV[ choroidal neovascularization; DA[ disc area.
FIGURE 4. Lower (ie, worse) best-corrected visual acuity at
baseline predicted, on average, a greater likelihood of gaining
‡15 letters at month 12 in patients treated with ranibizumab
for wet age-related macular degeneration. Data analyzed for pa-
tients in the ranibizumab 0.5 mg monthly and 0.5 mg as-needed
groups who had best-corrected visual acuity measured at both
baseline and month 12. Odds ratio, 4.6 (95% confidence
interval 2.1–10.5) from logistic regression model with baseline
best-corrected visual acuity, baseline total choroidal neovascula-
rization leakage area, and subretinal fluid presence at baseline as
covariates. BCVA[ best-corrected visual acuity.
FIGURE 5. Smaller total choroidal neovascularization leakage
area with subretinal fluid present at baseline predicted, on
average, a greater likelihood of best-corrected visual acuity
gain ‡15 letters at month 12 in patients treated with ranibizu-
mab for wet age-related macular degeneration. Data analyzed
for patients in the ranibizumab 0.5 mg monthly and 0.5 mg as-
needed groups who had best-corrected visual acuity measured
at both baseline and month 12. Odds ratio, 2.5 (95% confidence
interval 1.5–4.3) from logistic regression model with baseline
best-corrected visual acuity, baseline total choroidal neovascula-
rization leakage area, and subretinal fluid presence at baseline as
covariates. BCVA [ best-corrected visual acuity; CNV [
choroidal neovascularization; DA[ disc area; SRF[ subreti-
nal fluid.present at baseline, 41% of those with baseline total CNV
leakage area <_4.51 DA (n ¼ 282) gained >_15 letters at
month 12 vs 22% of patients with baseline total CNV
leakage area >4.51 DA (n ¼ 99; OR, 2.5; 95% CI 1.5–
4.3; from logistic regression model with baseline BCVA,1018 AMERICAN JOURNAL OFbaseline total CNV leakage area, and SRF presence at base-
line as covariates). In patients who did not have SRF pre-
sent at baseline, total CNV leakage area at baseline was
not predictive of BCVA gain >_15 letters at month 12.NOVEMBER 2015OPHTHALMOLOGY
FIGURE 6. Higher (ie, better) best-corrected visual acuity at baseline predicted, on average, a greater likelihood of achieving a
Snellen equivalent of 20/40 or better at month 12 in patients treated with ranibizumab for wet age-related macular degeneration.
Data shown are for patients in the ranibizumab 0.5 mg monthly and 0.5 mg as-needed groups who had best-corrected visual acuity
measured at both baseline and month 12. Dashed line[ fitted simple linear regression line. BCVA[ best-corrected visual acuity. BASELINE PREDICTORS FOR SNELLEN EQUIVALENT OF
20/40 OR BETTER AT MONTH 12: Significant baseline pre-
dictors for Snellen equivalent of 20/40 or better at month
12 for patients who had both baseline and month 12
BCVA values included BCVA, total CNV leakage area,
and presence of SRF.
Higher (ie, better) BCVA at baseline predicted a greater
likelihood of achieving a Snellen equivalent of 20/40 or
better at month 12 (Figure 6). Patients who achieved 20/
40 or better at month 12 (n ¼ 260; gray circles) had a
mean baseline BCVA of 60.7 letters (approximate Snellen
equivalent of 20/62.5) vs a mean baseline BCVA of 48.3
letters (approximate Snellen equivalent of 20/100) in
patients who did not achieve 20/40 at month 12 (n ¼
240; black circles). Each letter increase in baseline
BCVA increased the odds of achieving 20/40 or better by
1.11-fold (95% CI 1.09–1.13) at month 12.
Smaller total CNV leakage area at baseline also
predicted a greater likelihood of achieving a Snellen equiv-
alent of 20/40 or better at month 12 (Figure 7). Patients
who achieved 20/40 or better at month 12 (n ¼ 260; gray
circles) had a smaller mean total area of CNV leakage at
baseline (3.00 DA) compared with patients who did not
achieve 20/40 at month 12 (n ¼ 240; 3.69 DA). Each
DA decrease in total area of CNV leakage at baseline
increased the odds of achieving 20/40 or better by 1.2-
fold (95% CI 1.1–1.3) at month 12.
The presence of SRF at baseline was also predictive of
a greater likelihood of achieving a Snellen equivalent of
20/40 or better at month 12 (Figure 8). Overall, 56% ofVOL. 160, NO. 5 BASELINE PREDICTORS OF RESPONSEpatients with SRF present at baseline (n ¼ 381) achieved
20/40 or better at month 12 compared with 40% of patients
with SRF absent at baseline (n ¼ 119). Patients with SRF
present at baseline had 2-fold greater odds of achieving 20/
40 or better at month 12 compared with patients who did
not have SRF present at baseline (OR, 2.0; 95% CI 1.2–
3.3; from logistic regression model with baseline BCVA,
baseline total CNV leakage area, and SRF presence at base-
line as covariates).
 BASELINE PREDICTORS FOR TOTAL NUMBER OF INJEC-
TIONS OVER 12 MONTHS: A post hoc analysis of the total
number of injections over 12 months in ranibizumab
0.5 mg PRN patients with baseline and month 12 BCVA
values found that greater SRF thickness at baseline
predicted a greater likelihood of receiving more ranibizu-
mab injections in the first 12 months of the HARBOR
study (Figure 9). Patients with SRF thickness
>118.25 mm (n ¼ 117; black circles) required a mean of
8.9 injections over 12 months vs a mean of 7.3 injections
for patients with SRF <_118.25 mm (n ¼ 134; gray circles).
Similar results were obtained when the number of injec-
tions was evaluated as a continuous variable.DISCUSSION
ANTI-VEGF THERAPYWAS THE FIRST TREATMENT APPROVED
for wet AMD that showed a possibility of VA restoration in1019TO RANIBIZUMAB IN WET AMD
FIGURE 8. Subretinal fluid presence at baseline predicted, on
average, a greater likelihood of achieving 20/40 or better at
month 12 in patients treated with ranibizumab for wet age-
related macular degeneration. Data shown for patients in the
ranibizumab 0.5 mg monthly and 0.5 mg as-needed groups
who had best-corrected visual acuity measured at both baseline
and month 12. Odds ratio, 2.0 (95% confidence interval 1.2–
3.3) derived from logistic regression model with baseline best-
corrected visual acuity, baseline total choroidal neovasculariza-
tion leakage area, and subretinal fluid presence at baseline as
covariates. SRF[ subretinal fluid.
FIGURE 7. Smaller total choroidal neovascularization leakage area at baseline predicted, on average, a greater likelihood of achieving
20/40 or better at month 12 in patients treated with ranibizumab for wet age-related macular degeneration. Data shown are for pa-
tients in the ranibizumab 0.5 mgmonthly and 0.5 mg as-needed groups who had best-corrected visual acuity measured at both baseline
and month 12. Dashed line[ fitted simple linear regression line. BCVA[ best-corrected visual acuity; CNV[ choroidal neovas-
cularization; DA[ disc area.a previously poorly treatable disease.1–3 Despite the great
advancement in wet AMD treatment with anti-VEGF mol-
ecules, there is a need to develop additional approaches for1020 AMERICAN JOURNAL OFthose wet AMD patients who demonstrate suboptimal
response to anti-VEGF therapy. Identification of predictive
biomarkers of anti-VEGF response would enable the selec-
tion of those patients who will most benefit from novel ther-
apies. In addition, validated objective biomarkers predictive
of injection frequency with anti-VEGF molecules may
enable retina specialists to individualize dosing regimens
at the time of a patient’s first treatment.
A variety of baseline patient and ocular characteristics
predictive of treatment response have been explored in
previous wet AMD studies.4–6 In the current study, we
performed a retrospective exploratory analysis of the
large 12-month HARBOR data set to evaluate the corre-
lation of baseline characteristics that could serve as po-
tential predictive biomarkers of anti-VEGF response.
Our focus was on the anatomic/imaging and demographic
characteristics present at baseline and the potential asso-
ciations of these characteristics with visual function out-
comes at month 12 in patients receiving ranibizumab
0.5 mg monthly or PRN.
Significant baseline predictors of better VA outcomes at
month 12 in the ranibizumab 0.5 mg monthly and 0.5 mg
PRN groups included lower baseline BCVA, younger age
at baseline, and smaller total area of CNV leakage at base-
line. These findings provide further confirmation of base-
line predictors of visual outcomes in wet AMD patients
treated with ranibizumab,4,6,11,12 particularly in the PRN
group, where only the CATT data6 exist in such a large
cohort. Additionally, the CATT subanalysis identified
total foveal thickness and retinal pigment epitheliumNOVEMBER 2015OPHTHALMOLOGY
FIGURE 9. Greater subretinal fluid thickness at baseline predicted requiring, on average, a greater number of ranibizumab injections
in the first 12 months of study treatment in patients with wet age-related macular degeneration. Data shown for patients in the rani-
bizumab 0.5 mg monthly and 0.5 mg as-needed groups who had best-corrected visual acuity measured at both baseline and month 12.
Dashed line[ fitted simple linear regression line. SRF[ subretinal fluid.elevation on time-domain OCT as baseline anatomic pre-
dictors of VA outcomes at month 12.6 Although these
anatomic variables were included in the current HARBOR
subanalysis, they were not identified as significant covari-
ates for treatment response, possibly owing to differences
in the way the variables were defined or measured (SD
OCT was used in HARBOR, whereas time-domain OCT
was used in year 1 of CATT), or owing to differences in
how the statistical modeling was conducted between
studies.
In an effort to reduce the treatment burden associated
with frequent anti-VEGF injections, many retina special-
ists individualize treatment for their patients using variable
dosing regimens such as PRN and treat-and-extend.13,14
PRN treatment regimens with VEGF inhibitors resulted
in visual outcomes similar to monthly treatment when
VA and OCT criteria were used to assess the need for
re-treatment.8,15–21 In this subanalysis of the HARBOR
study, SRF thickness >118.25 mm at baseline predicted
requiring, on average, 1.6 more injections in year 1 of
HARBOR compared with patients whose SRF thickness
was <_118.25 mm at baseline. These data suggest that
greater SRF thickness at baseline may require more-
frequent injections in the first year of treatment.
A retrospective, exploratory, post hoc analysis of
pooled ranibizumab 0.5 mg data from 4 ranibizumab
trials in wet AMD patients (ANCHOR,1 MARINA,3VOL. 160, NO. 5 BASELINE PREDICTORS OF RESPONSEHARBOR,8 and PIER [Phase IIIb, Multicenter, Ran-
domized, Double-Masked, Sham Injection-Controlled
Study of the Efficacy and Safety of Ranibizumab in Sub-
jects With Subfoveal Choroidal Neovascularization
With or Without Classic CNV Secondary to Age-
Related Macular Degeneration study]22) also demon-
strated that patients who required >_10 injections in the
first 12 months of ranibizumab treatment (n ¼ 76) had
significantly greater mean SRF thickness at baseline
compared with patients who required <10 injections
(n ¼ 175). (Adamis AP et al. Presented at the 2012
Retina Society Annual Meeting, October 4–7, 2012;
Washington, DC). In this HARBOR subanalysis, the
presence of SRF at baseline was also associated with a
greater likelihood of achieving a Snellen equivalent of
20/40 or better at month 12, as well as a greater likeli-
hood of gaining >_15 letters when total CNV leakage
area <_4.51 DA was also present. It is possible that SRF
presence and/or thickness at baseline contributed to
poor baseline VA, and these patients had a greater likeli-
hood of achieving 20/40 vision with more-frequent treat-
ment compared with patients who started with a better
VA at baseline. It may also be possible that SRF provides
photoreceptors access to nutrients, allowing for better
functioning with continued anti-VEGF therapy over
time. Further study is warranted to confirm and help
elucidate the potential mechanism for this baseline1021TO RANIBIZUMAB IN WET AMD
characteristic leading to beneficial functional outcomes
with treatment.
In summary, this retrospective exploratory analysis of the
HARBOR study identified several baseline predictors asso-
ciated with VA outcomes at month 12 with ranibizumab
treatment in patients with wet AMD. Consistent with
other published reports, lower baseline BCVA, younger1022 AMERICAN JOURNAL OFage, and smaller total CNV leakage area and area of occult
CNV at baseline were identified as being predictive of more
VA gain, as was SRF presence at baseline. Understanding
which biomarkers are predictive of visual and treatment
frequency response to anti-VEGF treatment may help
retina specialists manage patient expectations and guide
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APPENDIX
Definitions as Derived From the Digital Angiography
Reading Center (DARC, New York, USA)
Macula dry: If at least 2 graders say that subretinal fluid
(SRF) thickness is not present and cystoid spaces ¼ ‘‘No’’
and intraretinal fluid ¼ ‘‘No’’ and at least 2 graders say
that pigment epithelial thickness is not present, then this
is set to Yes; otherwise it is set to No.
Macula dry-2: If cystoid spaces ¼ ‘‘No’’ and central sub-
field thickness average <275 mm and at least 2 graders say
that SRF thickness is not present, then this is set to Yes;
otherwise it is set to No.
Macula totally dry: If at least 2 graders say that SRF
thickness is not present and cystoid spaces ¼ ‘‘No’’ and
intraretinal fluid ¼ ‘‘No’’ and at least 2 graders say that
pigment epithelial thickness is not present and central sub-
field thickness average is <275 mm, then this is set to Yes;
otherwise it is set to No.1023.e1 AMERICAN JOURNAL OFMacula totally dry-2: If cystoid spaces ¼ ‘‘No’’ and cen-
tral subfield thickness average <275 mm and at least 2
graders say that SRF thickness is not present and at least
2 graders say that pigment epithelial thickness is not pre-
sent, then this is set to Yes; otherwise it is set to No.
Retina dry: If at least 2 graders say that SRF thickness is
not present and cystoid spaces ¼ ‘‘No’’ and intraretinal
fluid¼ ‘‘No’’ then this is set to Yes; otherwise it is set to No.
Retina dry-2: If cystoid spaces ¼ ‘‘No’’ and central sub-
field thickness average <275 mm, then this is set to Yes;
otherwise it is set to No.
Retinal pigment epithelium (RPE) rip outside: Anything
not under the fovea but within 3000 mm of the fovea.
RPE rip remote: Anything farther than 3000 mm from
the fovea.
SRF presence: Indicates whether SRF is present or not.
SRF thickness: The numeric value of the thickness; a
thickness of 0 means that SRF is not present.NOVEMBER 2015OPHTHALMOLOGY
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